Publications by authors named "M Hromadka"
Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make it the optimal P2Y12 inhibitor for CS-AMI, in terms of both efficacy and safety.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the 1-year outcomes of the ECMO-CS trial, which compared immediate ECMO initiation to an early conservative approach in patients with severe cardiogenic shock.
- Results showed no significant difference in all-cause mortality or other critical outcomes between the two strategies after one year.
- However, there was a suggestion that immediate ECMO could be more beneficial for patients with significantly low mean arterial pressure at baseline, indicating a possible targeted use for this treatment strategy.
Introduction And Objectives: Multivessel primary percutaneous coronary intervention (pPCI) is still often used in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS). The study aimed to compare the characteristics and prognosis of patients with CS-STEMI and multivessel coronary disease (MVD) treated with culprit vessel-only pPCI or multivessel-pPCI during the initial procedure.
Material And Methods: From 2016 to 2020, 23,703 primary PCI patients with STEMI were included in a national all-comers registry of cardiovascular interventions.